MedTrace Logo

Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer

NCT02474641 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2324

Last updated 2024-03-21

No results posted yet for this study

Summary

Hypofractionation with simultaneous integrated boost has been investigated in a few trials and appears to be safe and feasible.

Investigators initiated this multicenter two-armed phase III prospective trial to analyse the non-inferiority of hypofractionation with simultaneous integrated boost in patients with early breast cancer in comparison to standard fractionation.

Conditions

  • Early-Stage Breast Carcinoma

Interventions

RADIATION

Standard Radiation

Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially

RADIATION

Hypofractionation with SIB

Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed

Sponsors & Collaborators

  • University of Luebeck

    collaborator OTHER

  • University Hospital Schleswig-Holstein

    lead OTHER

Principal Investigators

  • Jürgen Dunst, MD · University Medical Center Schleswig-Holstein (UKSH)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-16
Primary Completion
2019-01-08
Completion
2028-03-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02474641 on ClinicalTrials.gov